Testing effectiveness (Phase 2)Ended earlyNCT00818649
What this trial is testing
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Who this might be right for
LeukemiaMyelodysplastic Syndrome
Masonic Cancer Center, University of Minnesota 16